エビの疾病診断市場：キット、疾病、エンドユーザー別-2025-2030年の世界予測

エビの疾病診断市場は、2023年に4億4,318万米ドルと評価され、2024年には4億7,810万米ドルに達すると予測され、CAGR 7.92%で成長し、2030年には7億5,583万米ドルに達すると予測されています。

調査手法の範囲は、エビの健康維持と持続可能な養殖に不可欠な、エビ個体群の病気を特定するために設計されたさまざまな診断ツールと手法をカバーしています。このような診断の必要性は、世界のエビ需要の増加と、それに伴う養殖業の増加に起因しており、疾病の発生は大きな経済的損失とサプライチェーンの混乱につながります。エビの疾病診断の用途には、白点症候群、伝染性皮下脂肪症、造血壊死ウイルスなどの疾病の早期発見と予防が含まれます。最終用途には、主に養殖場、水生生物専門の動物病院、診断研究所などが含まれます。主な市場成長要因としては、急成長する水産養殖産業、診断ツールの技術進歩、持続可能な水産養殖の必要性に対する意識の高まりなどが挙げられます。現場条件下で容易に利用できる、費用対効果が高く、即応性の高い診断ツールの開発に機会があります。もうひとつの可能性は、AIや機械学習などのデジタル技術を診断に統合することで、予測分析や疾病管理戦略の改善を可能にすることです。

しかし、高度な診断ツールに関連する高コスト、新興国市場のインフラ不足、規制上の課題などの制約が、市場の成長を阻害する可能性があります。業界はまた、標準化された診断手順を実現し、正確で信頼性の高い結果を確保するという課題にも直面しています。技術革新と研究が必要な分野には、低コストの携帯型診断キットの開発、バイオセンサー技術の改良、耐病性のための遺伝子ソリューションの探求などがあります。学術機関と業界各社との研究提携に投資することで、耐病性エビ株の画期的な発見が期待できます。市場競争は緩やかであるため、各社は競争力を維持するために継続的な技術革新を行う必要があります。各社は地理的範囲を拡大することに重点を置くべきで、養殖業が成長しつつある新興市場をターゲットにすることも考えられます。また、持続可能で環境に優しいソリューションを強調することで、環境に配慮した生産慣行に対する消費者の関心の高まりに対応することができます。

市場力学：急速に進化するエビの疾病診断市場の主要市場洞察の解明

エビの疾病診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で拡大するエビの生産と輸出活動
  • エビの病気に取り組む官民の意識向上イニシアティブと福祉プロジェクト
  • エビ養殖の品質に関する規制と効率的な疾病検出ツールの必要性
• 市場抑制要因
  • 複雑な検査手順と訓練された人材の必要性
• 市場機会
  • エビ診断技術と迅速検査法の進歩
  • エビ養殖活動の拡大に向けた新たな投資
• 市場の課題
  • 偽陽性やエビの疾病診断の不正確さに伴う限界

ポーターのファイブフォースエビの疾病診断市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、エビの疾病診断市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：エビの疾病診断市場における外部からの影響の把握

外部マクロ環境要因は、エビの疾病診断市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析エビの疾病診断市場における競合情勢の把握

エビの疾病診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスエビの疾病診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、エビの疾病診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨エビの疾病診断市場における成功への道筋を描く

エビの疾病診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中でエビの生産と輸出が拡大
    • エビの病気に取り組む官民の啓発活動と福祉プロジェクト
    • 高品質のエビ養殖のための規制と効率的な病気検出ツールの必要性
  • 抑制要因
    • 複雑なテスト手順と訓練を受けた人員の必要性
  • 機会
    • エビの診断技術と迅速検査方法の進歩
    • エビ養殖活動の拡大への新たな投資
  • 課題
    • エビの疾病診断の誤検出と不正確さに関連する制限
• 市場セグメンテーション分析
  • キット：病原体を迅速かつ簡単に検出するための迅速検査キットの採用が増加
  • 病気：白斑症候群ウイルス（WSSV）は伝染性が非常に高く、質の高いPCR検査と組織学的検査が必要です。
  • エンドユーザー：漁業におけるエビの病気の発生率が増加しており、エビの疾病診断戦略の展開が必要
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 エビの疾病診断市場キット

• アッセイベースキット
• 迅速検査キット

第7章 エビの疾病診断市場：疾患別

• 早期死亡症候群
• タウラ症候群ウイルス
• 白斑症候群ウイルス
• イエローヘッドまたはギル関連ウイルス

第8章 エビの疾病診断市場：エンドユーザー別

• 水産養殖・海洋研究所
• 教育・調査機関
• 漁業

第9章 南北アメリカのエビの疾病診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のエビの疾病診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのエビの疾病診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • エビ養殖業者向けに低コストの白点病検査を開発する米国のプロジェクト
  • ViAqua TherapeuticsがRNAベースの養殖病害管理のための資金を確保
  • アクアトレック、養殖場向け診断サービスの開発に向けた調査契約を締結
• 戦略分析と提言

企業一覧

• 3 Little Fish Sdn Bhd
• Amazing Biotech
• Aquaintech Inc.
• Arachem（M）Sdn Bhd
• Bioneer Corporation
• Blue Aqua International Pte. Ltd.
• CD Genomics
• China Guangzhou BioKey Healthy Technology Co. Ltd
• DSM Austria GmbH
• Forte Biotech
• GeneReach Biotechnology Corp.
• GeneReach Biotechnology Corporation
• Genics Pty. Ltd.
• Illumina, Inc.
• Innocreate Bioscience Co., Ltd.
• Lab-Ind Resource Sdn. Bhd.
• Laboratory Corporation of America Holdings
• Mahesh Aqua Holdings（Pvt）Ltd.
• Mylab Discovery Solutions Pvt. Ltd.
• PT Riset Nusantara Genetika（Nusantics）
• Randox Laboratories Ltd.
• Reagen LLC
• Ring Biotechnology Co Ltd.
• Speedy Assay Sdn. Bhd.
• SUREBIO
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. SHRIMP DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. SHRIMP DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. SHRIMP DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SHRIMP DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SHRIMP DISEASE DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY ASSAY BASED KIT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY RAPID TESTING KIT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY EARLY MORTALITY SYNDROME, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY TAURA SYNDROME VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY WHITE SPOT SYNDROME VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY YELLOW HEAD OR GILL ASSOCIATED VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY AQUACULTURE & MARINE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY EDUCATION & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY FISHERIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 30. CANADA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 47. CHINA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 50. INDIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 102. ITALY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 114. POLAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 117. QATAR SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY KIT, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM SHRIMP DISEASE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 146. SHRIMP DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. SHRIMP DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Shrimp Disease Diagnostics Market was valued at USD 443.18 million in 2023, expected to reach USD 478.10 million in 2024, and is projected to grow at a CAGR of 7.92%, to USD 755.83 million by 2030.

The scope of the shrimp disease diagnostics market covers a range of diagnostic tools and methodologies designed to identify diseases in shrimp populations, vital to maintaining shrimp health and ensuring sustainable aquaculture practices. The necessity of these diagnostics arises from the increasing global demand for shrimp and the corresponding rise in aquaculture, where disease outbreaks can lead to significant economic losses and supply chain disruptions. Applications of shrimp disease diagnostics include early detection and prevention of diseases like white spot syndrome, infectious hypodermal and hematopoietic necrosis virus, among others. End-use scope primarily includes aquaculture farms, veterinary clinics specializing in aquatic creatures, and diagnostic laboratories. Key market growth factors include the burgeoning aquaculture industry, technological advancements in diagnostic tools, and increased awareness of the need for sustainable aqua farming practices. Opportunities lie in developing cost-effective, quick-response diagnostic tools that can be easily utilized in field conditions. Another potential opportunity is the integration of digital technologies such as AI and machine learning in diagnostics, allowing for predictive analytics and improved disease management strategies.

However, limitations such as high costs associated with advanced diagnostic tools, lack of infrastructure in developing regions, and regulatory challenges could impede market growth. The industry also faces challenges in achieving standardized diagnostic procedures and ensuring accuracy and reliability outcomes. Areas ripe for innovation and research include developing low-cost portable diagnostic kits, improving biosensor technology, and exploring genetic solutions for disease resistance. Investing in research partnerships between academic institutions and industry players could foster breakthroughs in disease-resistant shrimp strains. The market is characterized by moderate competition, requiring players to continuously innovate to maintain a competitive edge. Companies should focus on expanding their geographic reach, possibly targeting emerging markets with growing aquaculture activities. Emphasizing sustainable and eco-friendly solutions will also cater to the increasing consumer focus on environmentally responsible production practices.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Shrimp Disease Diagnostics Market

The Shrimp Disease Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing shrimp production and export activities worldwide
  • Public-private awareness initiatives and welfare projects to tackle shrimp diseases
  • Regulations for quality shrimp farming and need for efficient disease detection tools
• Market Restraints
  • Complex testing procedures and need for trained personnel
• Market Opportunities
  • Advancements in shrimp diagnostics technologies and rapid testing methods
  • New investments in expansion of shrimp farming activities
• Market Challenges
  • Limitations associated with false positives and inaccuracy of shrimp disease diagnostics

Porter's Five Forces: A Strategic Tool for Navigating the Shrimp Disease Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Shrimp Disease Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Shrimp Disease Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Shrimp Disease Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Shrimp Disease Diagnostics Market

A detailed market share analysis in the Shrimp Disease Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Shrimp Disease Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Shrimp Disease Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Shrimp Disease Diagnostics Market

A strategic analysis of the Shrimp Disease Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Shrimp Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include 3 Little Fish Sdn Bhd, Amazing Biotech, Aquaintech Inc., Arachem (M) Sdn Bhd, Bioneer Corporation, Blue Aqua International Pte. Ltd., CD Genomics, China Guangzhou BioKey Healthy Technology Co. Ltd, DSM Austria GmbH, Forte Biotech, GeneReach Biotechnology Corp., GeneReach Biotechnology Corporation, Genics Pty. Ltd., Illumina, Inc., Innocreate Bioscience Co., Ltd., Lab-Ind Resource Sdn. Bhd., Laboratory Corporation of America Holdings, Mahesh Aqua Holdings (Pvt) Ltd., Mylab Discovery Solutions Pvt. Ltd., PT Riset Nusantara Genetika (Nusantics), Randox Laboratories Ltd., Reagen LLC, Ring Biotechnology Co Ltd., Speedy Assay Sdn. Bhd., SUREBIO, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Shrimp Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Kit, market is studied across Assay Based Kit and Rapid Testing Kit.
• Based on Disease, market is studied across Early Mortality Syndrome, Taura Syndrome Virus, White Spot Syndrome Virus, and Yellow Head or Gill Associated Virus.
• Based on End User, market is studied across Aquaculture & Marine Laboratories, Education & Research Institutes, and Fisheries.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing shrimp production and export activities worldwide
    • 5.1.1.2. Public-private awareness initiatives and welfare projects to tackle shrimp diseases
    • 5.1.1.3. Regulations for quality shrimp farming and need for efficient disease detection tools
  • 5.1.2. Restraints
    • 5.1.2.1. Complex testing procedures and need for trained personnel
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in shrimp diagnostics technologies and rapid testing methods
    • 5.1.3.2. New investments in expansion of shrimp farming activities
  • 5.1.4. Challenges
    • 5.1.4.1. Limitations associated with false positives and inaccuracy of shrimp disease diagnostics
• 5.2. Market Segmentation Analysis
  • 5.2.1. Kit: Growing adoption of rapid testing kits for quick and easy detection of pathogens
  • 5.2.2. Disease: Highly contagious nature of white spot syndrome virus (WSSV) necessitating quality PCR and histological tests
  • 5.2.3. End User: Rising incidences of shrimp disease outbreaks in fisheries necessitating deployment of shrimp disease diagnostics strategies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Shrimp Disease Diagnostics Market, by Kit

• 6.1. Introduction
• 6.2. Assay Based Kit
• 6.3. Rapid Testing Kit

7. Shrimp Disease Diagnostics Market, by Disease

• 7.1. Introduction
• 7.2. Early Mortality Syndrome
• 7.3. Taura Syndrome Virus
• 7.4. White Spot Syndrome Virus
• 7.5. Yellow Head or Gill Associated Virus

8. Shrimp Disease Diagnostics Market, by End User

• 8.1. Introduction
• 8.2. Aquaculture & Marine Laboratories
• 8.3. Education & Research Institutes
• 8.4. Fisheries

9. Americas Shrimp Disease Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Shrimp Disease Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Shrimp Disease Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. US Project to Develop Low-Cost White Spot Test for Shrimp Farmers
  • 12.3.2. ViAqua Therapeutics Secures Funding for RNA-based Aquaculture Disease Management
  • 12.3.3. Aquatreck Signs Research Agreement to Develop Diagnostic Services for Fish Farms
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 3 Little Fish Sdn Bhd
• 2. Amazing Biotech
• 3. Aquaintech Inc.
• 4. Arachem (M) Sdn Bhd
• 5. Bioneer Corporation
• 6. Blue Aqua International Pte. Ltd.
• 7. CD Genomics
• 8. China Guangzhou BioKey Healthy Technology Co. Ltd
• 9. DSM Austria GmbH
• 10. Forte Biotech
• 11. GeneReach Biotechnology Corp.
• 12. GeneReach Biotechnology Corporation
• 13. Genics Pty. Ltd.
• 14. Illumina, Inc.
• 15. Innocreate Bioscience Co., Ltd.
• 16. Lab-Ind Resource Sdn. Bhd.
• 17. Laboratory Corporation of America Holdings
• 18. Mahesh Aqua Holdings (Pvt) Ltd.
• 19. Mylab Discovery Solutions Pvt. Ltd.
• 20. PT Riset Nusantara Genetika (Nusantics)
• 21. Randox Laboratories Ltd.
• 22. Reagen LLC
• 23. Ring Biotechnology Co Ltd.
• 24. Speedy Assay Sdn. Bhd.
• 25. SUREBIO
• 26. Thermo Fisher Scientific Inc.